FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
Adjuvant therapy with a modified FOLFIRINOX regimen led to significantly longer survival than gemcitabine among patients with resected pancreatic cancer, at the expense of a hig...
Publications
2 shownRamucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations have poor prognosis. We aimed to establish the efficacy of ramucirumab in patien...
Frequent Co-Authors
Researcher Info
- h-index
- 2
- Publications
- 2
- Citations
- 4,266
- Institution
- Centre Hospitalier Universitaire de Montpellier
External Links
Identifiers
- ORCID
- 0000-0002-8958-2793
Impact Metrics
h-index
2
h-index: Number of publications with at least h citations each.